Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
67296-1562-02 67296-1562 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2018 In Use
67296-1562-01 67296-1562 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2018 In Use
67457-0621-02 67457-0621 TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular May 8, 2023 In Use
67457-0622-05 67457-0622 TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 200.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular May 8, 2023 In Use
67457-0622-99 67457-0622 TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 200.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular Aug. 19, 2024 In Use
67457-0623-10 67457-0623 TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular May 8, 2023 In Use
67457-0623-99 67457-0623 TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular Aug. 19, 2024 In Use
00013-2576-91 00013-2576 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
00013-2576-05 00013-2576 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 12, 2024 In Use
00069-0277-02 00069-0277 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 19, 2024 In Use
00069-0358-20 00069-0358 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 19, 2024 In Use
00121-4759-50 00121-4759 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 22, 2024 In Use
00069-1542-20 00069-1542 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous July 22, 2024 In Use
00338-9665-01 00338-9665 Doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 26, 2024 In Use
00338-9667-01 00338-9667 Doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 26, 2024 In Use
00338-9777-01 00338-9777 Cyclophosphamide injection, solution Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
00338-9779-01 00338-9779 Cyclophosphamide injection, solution Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
00409-3414-01 00409-3414 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Feb. 2, 2006 In Use
00409-3414-11 00409-3414 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Aug. 26, 2024 In Use
00409-5255-25 00409-5255 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Nov. 14, 2022 In Use
00904-7267-61 00904-7267 Dexamethasone Dexamethasone 6.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 26, 2024 In Use
00904-7444-61 00904-7444 Dexamethasone Dexamethasone 2.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 26, 2024 In Use
25021-0416-01 25021-0416 Plerixafor Plerixafor 20.0 mg/mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous Aug. 1, 2024 In Use
25021-0471-74 25021-0471 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Sept. 15, 2024 In Use
31722-0303-31 31722-0303 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 3, 2024 In Use

Found 10,000 results in 6 milliseconds — Export these results